---
title: "Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy: Clinical trials questions"
description: "Clinical trials questions on Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results, Subgroup results, and Long-term results. Questions: What trial supported Vyndamax approval (ATTR-ACT)? Who was eligible for ATTR-ACT, the trial behind Vyndamax approval? Vyndamax ATTR-ACT trial: did Vyndaqel reduce death and cardiovascular hospitalizations? Vyndamax ATTR-ACT trial: how much did Vyndaqel lower the risk of death? 6 further questions follow. 10 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/clinical-trials"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy: Clinical trials questions

Manufacturer: Pfizer Inc  
Prescribing information: [Vyndaqel and Vyndamax](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685)

## Clinical trials

<a id="vyndamax-attr-act-design"></a>

### What trial supported Vyndamax approval (ATTR-ACT)?

> “Approval of VYNDAMAX was based on ATTR-ACT, a phase 3, multicenter, international, randomized, double-blind, placebo-controlled study, which evaluated pooled VYNDAQEL<sup>®</sup> (tafamidis meglumine) doses of 20 mg and 80 mg in 441 patients with wild-type or hereditary transthyretin cardiac amyloidosis*—a single VYNDAMAX 61-mg capsule is bioequivalent<sup>†</sup> to VYNDAQEL 80 mg (four 20-mg capsules) and is not interchangeable on a per-mg basis.<sup>1-3</sup>”

Source: [VYNDAMAX: Clinical Efficacy in ATTR‑CM | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/efficacy-data#:~:text=Approval%20of%20VYNDAMAX%20was%20based,not%20interchangeable%20on%20a%20per%2Dmg)

> “As determined by the predefined 90% confidence interval criteria of 80% to 125% bioequivalence limits for tafamidis area under curve (AUC) and peak plasma concentration (Cmax) after repeated oral daily dosing for 7 days.<sup>2</sup>”

Source: [VYNDAMAX: Clinical Efficacy in ATTR‑CM | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/efficacy-data#:~:text=As%20determined%20by%20the%20predefined,oral%20daily%20dosing%20for%207)

> “Patients were randomized in a 1:2:2 ratio to receive VYNDAQEL 20 mg (n=88), VYNDAQEL 80 mg (administered as four 20-mg VYNDAQEL capsules) (n=176), or matching placebo (n=177) once daily for 30 months, in addition to standard of care (e.g., diuretics). Treatment assignment was stratified by the presence or absence of a variant TTR genotype as well as baseline disease severity (NYHA Class). Transplant patients were excluded from this study.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=Patients%20were%20randomized%20in%20a,were%20excluded%20from%20this%20study.)

<a id="vyndamax-attr-act-eligibility"></a>

### Who was eligible for ATTR-ACT, the trial behind Vyndamax approval?

> “Select inclusion criteria<sup>4</sup>
> Patients between 18 and 90 years of age
> Confirmation of ATTR cardiac amyloidosis, wild-type or hereditary
> Echocardiography with an end-diastolic interventricular septal wall thickness >12 mm
> History of heart failure with at least 1 prior hospitalization for heart failure, or clinical evidence of heart failure (without hospitalization)<sup>||</sup>
> NT-proBNP level ≥600 pg/mL
> 6MWT >100 m
> Manifested in signs or symptoms of volume overload or elevated intracardiac pressures requiring treatment with a diuretic for improvement; an NT-proBNP level greater than or equal to 600 pg/mL; and a 6MWT distance exceeding 100 m.<sup>3</sup>”

Source: [VYNDAMAX: Study Design | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/study-design#:~:text=Select%20inclusion,a%206MWT%20distance%20exceeding%20100)

> “Select exclusion criteria<sup>4</sup>
> Heart failure unrelated to ATTR cardiac amyloidosis
> NYHA class IV heart failure
> Light-chain amyloidosis
> History of liver or heart transplantation
> Implanted cardiac mechanical assist device<sup>¶</sup>
> Patients with a permanent pacemaker or implanted cardiac defibrillator were permitted in this study<sup>4</sup>
> Previous VYNDAQEL treatment
> eGFR <25 mL/min/1.73 m<sup>2</sup>
> Liver transaminase levels >2x the upper limit of normal
> mBMI <600
> Concurrent treatment with NSAIDs,<sup>#</sup> tauroursodeoxycholate, doxycycline, calcium channel blockers, or digitalis
> Cardiac mechanical assist device (CMAD) term utilized to cover LVAD.<sup>3</sup>
> Select NSAIDs were permitted, eg, aspirin, ibuprofen, naproxen.<sup>3</sup>”

Source: [VYNDAMAX: Study Design | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/study-design#:~:text=Select%20exclusion,were%20permitted%2C%20eg%2C%20aspirin%2C%20ibuprofen%2C)

## Study results

<a id="vyndamax-attr-act-primary-endpoint"></a>

### Vyndamax ATTR-ACT trial: did Vyndaqel reduce death and cardiovascular hospitalizations?

> “The primary analysis used a hierarchical combination applying the method of Finkelstein-Schoenfeld (F-S) to all-cause mortality and frequency of cardiovascular-related hospitalizations, which was defined as the number of times a subject was hospitalized (i.e., admitted to a hospital) for cardiovascular-related morbidity. The method compared each patient to every other patient within each stratum in a pair-wise manner that proceeded in a hierarchical fashion using all-cause mortality followed by frequency of cardiovascular-related hospitalizations when patients could not be differentiated based on mortality.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=The%20primary%20analysis%20used%20a,be%20differentiated%20based%20on%20mortality.)

> “This analysis demonstrated a significant reduction (p=0.0006) in all-cause mortality and frequency of cardiovascular-related hospitalizations in the pooled VYNDAQEL 20-mg and 80-mg groups versus placebo (Table 2).”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=This%20analysis%20demonstrated%20a%20significant,groups%20versus%20placebo%20%28Table%202%29.)

> “Table 2: Primary Analysis Using Finkelstein-Schoenfeld (F-S) Method of All-Cause Mortality and Frequency of Cardiovascular-Related Hospitalizations
> Primary Analysis	Pooled VYNDAQEL
> N=264	Placebo
> N=177
>
> *
> Heart transplantation and cardiac mechanical assist device implantation are considered indicators of approaching end stage. As such, these subjects are treated in the analysis as equivalent to death. Therefore, such subjects are not included in the count of "Number of Subjects Alive at Month 30" even if such subjects are alive based on 30 month vital status follow-up assessment.
>
>
>
> Number (%) of Subjects Alive* at Month 30
>
>
>
> 186 (70.5)
>
>
>
> 101 (57.1)
>
>
>
>
> Mean Number of Cardiovascular-related Hospitalizations During 30 months (per patient per year) Among Those Alive at Month 30
>
>
>
> 0.297
>
>
>
> 0.455
>
>
>
>
> p-value from F-S Method
>
>
>
> 0.0006”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=Table%202%3A%20Primary%20Analysis%20Using,0.0006)

Note: Table 2 columns are pooled VYNDAQEL (N=264) and placebo (N=177), in that order. ATTR-ACT studied VYNDAQEL (tafamidis meglumine) 20 mg and 80 mg, pooled. The label recommends VYNDAQEL 80 mg or VYNDAMAX 61 mg once daily and states that the two are not substitutable on a per mg basis; the Vyndamax HCP site states that VYNDAMAX approval was based on ATTR-ACT and that one VYNDAMAX 61-mg capsule is bioequivalent to VYNDAQEL 80 mg. In ATTR-ACT, patients received study drug once daily for 30 months.

<a id="vyndamax-attr-act-mortality"></a>

### Vyndamax ATTR-ACT trial: how much did Vyndaqel lower the risk of death?

> “The hazard ratio from the all-cause mortality Cox-proportional hazard model for pooled VYNDAQEL versus placebo was 0.70 (95% confidence interval [CI] 0.51, 0.96), indicating a 30% relative reduction in the risk of death relative to the placebo group (p=0.026). Approximately 80% of total deaths were cardiovascular-related in both treatment groups.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=The%20hazard%20ratio%20from%20the,cardiovascular%2Drelated%20in%20both%20treatment%20groups.)

> “Heart transplants and cardiac mechanical assist devices treated as death. Hazard ratio from Cox proportional hazards model with treatment, TTR genotype (variant and wild-type), and NYHA baseline classification (NYHA Classes I and II combined and NYHA Class III) as factors.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=Heart%20transplants%20and%20cardiac%20mechanical,NYHA%20Class%20III%29%20as%20factors.)

> “All-cause mortality as an individual component: VYNDAQEL significantly reduced the risk of all-cause mortality vs placebo, p=0.026 at month 30.<sup>1,3,4</sup>”

Source: [VYNDAMAX: Clinical Efficacy in ATTR‑CM | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/efficacy-data#:~:text=All%2Dcause%20mortality%20as%20an%20individual,vs%20placebo%2C%20p%3D0.026%20at%20month)

Note: ATTR-ACT studied VYNDAQEL (tafamidis meglumine) 20 mg and 80 mg, pooled. The label recommends VYNDAQEL 80 mg or VYNDAMAX 61 mg once daily and states that the two are not substitutable on a per mg basis; the Vyndamax HCP site states that VYNDAMAX approval was based on ATTR-ACT and that one VYNDAMAX 61-mg capsule is bioequivalent to VYNDAQEL 80 mg. In ATTR-ACT, patients received study drug once daily for 30 months.

<a id="vyndamax-attr-act-hospitalizations"></a>

### Vyndamax ATTR-ACT trial: did Vyndaqel reduce cardiovascular hospitalizations vs placebo?

> “There were significantly fewer cardiovascular-related hospitalizations with VYNDAQEL compared with placebo with a reduction in risk of 32% corresponding to a Relative Risk Ratio of 0.68 (Table 3).”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=There%20were%20significantly%20fewer%20cardiovascular%2Drelated,Ratio%20of%200.68%20%28Table%203%29.)

> “Table 3: Cardiovascular-Related Hospitalization Frequency
> 	Pooled VYNDAQEL
> N=264	Placebo
> N=177
>
> *
> This analysis was based on a Poisson regression model with treatment, TTR genotype (variant and wild-type), New York Heart Association (NYHA). Baseline classification (NYHA Classes I and II combined and NYHA Class III), treatment-by-TTR genotype interaction, and treatment-by-NYHA baseline classification interaction terms as factors.
>
>
>
> Total (%) Number of Subjects with Cardiovascular-related Hospitalizations
>
>
>
> 138 (52.3)
>
>
>
> 107 (60.5)
>
>
>
>
> Cardiovascular-related Hospitalizations per Year*
>
>
>
> 0.48
>
>
>
> 0.70
>
>
>
>
> Pooled VYNDAQEL vs Placebo Treatment Difference (Relative Risk Ratio)*
>
>
>
> 0.68
>
>
>
>
> p-value*
>
>
>
> <0.0001”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=Table%203%3A%20Cardiovascular%2DRelated%20Hospitalization%20Frequency,%3C0.0001)

> “CV-related hospitalizations as an individual component: VYNDAQEL significantly reduced the risk of frequency of CV-related hospitalizations vs placebo, p<0.0001 at month 30.<sup>1,3,4</sup>”

Source: [VYNDAMAX: Clinical Efficacy in ATTR‑CM | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/efficacy-data#:~:text=CV%2Drelated%20hospitalizations%20as%20an%20individual,vs%20placebo%2C%20p%3C0.0001%20at%20month)

> “~4 patient-years of treatment are needed to prevent 1 CV-related hospitalization<sup>4</sup>”

Source: [VYNDAMAX: Clinical Efficacy in ATTR‑CM | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/efficacy-data#:~:text=~4%20patient%2Dyears%20of%20treatment%20are%20needed%20to%20prevent%201%20CV%2Drelated)

Note: Table 3 columns are pooled VYNDAQEL (N=264) and placebo (N=177), in that order. The patient-years figure is from the efficacy page of the Vyndamax HCP site, which cites Maurer and Mann, JACC Basic Transl Sci 2018. ATTR-ACT studied VYNDAQEL (tafamidis meglumine) 20 mg and 80 mg, pooled. The label recommends VYNDAQEL 80 mg or VYNDAMAX 61 mg once daily and states that the two are not substitutable on a per mg basis; the Vyndamax HCP site states that VYNDAMAX approval was based on ATTR-ACT and that one VYNDAMAX 61-mg capsule is bioequivalent to VYNDAQEL 80 mg. In ATTR-ACT, patients received study drug once daily for 30 months.

<a id="vyndamax-attr-act-6mwt-kccq"></a>

### Vyndamax ATTR-ACT trial: did Vyndaqel slow decline in walking distance and KCCQ score?

> “The treatment effects of VYNDAQEL on functional capacity and health status were assessed by the 6-Minute Walk Test (6MWT) and the Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) score, respectively. A significant treatment effect favoring VYNDAQEL was first observed at Month 6 and remained consistent through Month 30 on both 6MWT distance and KCCQ-OS score (Figure 2 and Table 4).”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=The%20treatment%20effects%20of%20VYNDAQEL,%28Figure%202%20and%20Table%204%29.)

> “Table 4: 6MWT Distance and KCCQ-OS Scores
> Abbreviations: 6MWT = 6-Minute Walk Test; KCCQ-OS = Kansas City Cardiomyopathy Questionnaire-Overall Summary; SD = standard deviation; LS = least squares; SE = standard error; CI = confidence interval
>
>
> Endpoints
>
>
>
> Baseline Mean (SD)
>
>
>
> Change from Baseline to Month 30, LS Mean (SE)
>
>
>
> Treatment Difference from Placebo
> LS Mean (95% CI)
>
>
>
>
> Pooled VYNDAQEL
> N=264
>
>
>
> Placebo
> N=177
>
>
>
> Pooled VYNDAQEL
>
>
>
> Placebo
>
>
>
>
> 6MWT
> (meters)
>
>
>
> 351
> (121)
>
>
>
> 353
> (126)
>
>
>
> -55
> (5)
>
>
>
> -131
> (10)
>
>
>
> 76
> (58, 94)
>
>
>
>
> KCCQ-OS
>
>
>
> 67
> (21)
>
>
>
> 66
> (22)
>
>
>
> -7
> (1)
>
>
>
> -21
> (2)
>
>
>
> 14
> (9, 18)”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=Table%204%3A%206MWT%20Distance%20and,%289%2C%2018%29)

> “The Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) score is composed of four domains including Total Symptoms (Symptom Frequency and Symptom Burden), Physical Limitation, Quality of Life, and Social Limitation. The Overall Summary score and domain scores range from 0 to 100, with higher scores representing better health status.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=The%20Kansas%20City%20Cardiomyopathy%20Questionnaire%2DOverall%20Summary%20%28KCCQ%2DOS%29%20score%20is,scores%20representing%20better%20health%20status.)

Note: Table 4 values follow the header order: baseline mean (SD) for pooled VYNDAQEL and placebo, change from baseline to Month 30 as LS mean (SE) for pooled VYNDAQEL and placebo, and the treatment difference from placebo as LS mean (95% CI). ATTR-ACT studied VYNDAQEL (tafamidis meglumine) 20 mg and 80 mg, pooled. The label recommends VYNDAQEL 80 mg or VYNDAMAX 61 mg once daily and states that the two are not substitutable on a per mg basis; the Vyndamax HCP site states that VYNDAMAX approval was based on ATTR-ACT and that one VYNDAMAX 61-mg capsule is bioequivalent to VYNDAQEL 80 mg. In ATTR-ACT, patients received study drug once daily for 30 months.

<a id="vyndamax-attr-act-biomarkers"></a>

### Vyndamax ATTR-ACT trial: did NT-proBNP and troponin favor Vyndaqel over placebo?

> “Biomarkers associated with heart failure (NT-proBNP and Troponin I) favored VYNDAQEL over placebo.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=Biomarkers%20associated%20with%20heart%20failure,I%29%20favored%20VYNDAQEL%20over%20placebo.)

Note: ATTR-ACT studied VYNDAQEL (tafamidis meglumine) 20 mg and 80 mg, pooled. The label recommends VYNDAQEL 80 mg or VYNDAMAX 61 mg once daily and states that the two are not substitutable on a per mg basis; the Vyndamax HCP site states that VYNDAMAX approval was based on ATTR-ACT and that one VYNDAMAX 61-mg capsule is bioequivalent to VYNDAQEL 80 mg. In ATTR-ACT, patients received study drug once daily for 30 months.

<a id="vyndamax-attr-act-20mg-vs-80mg"></a>

### Vyndamax ATTR-ACT trial: did Vyndaqel 20 mg and 80 mg give similar results?

> “Results of the primary analysis, 6MWT at Month 30 and KCCQ-OS at Month 30 were statistically significant for both the 80-mg and 20-mg doses of VYNDAQEL vs. placebo, with similar results for both doses.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=Results%20of%20the%20primary%20analysis%2C,similar%20results%20for%20both%20doses.)

> “A proprietary TTR stabilization assay was utilized as a pharmacodynamic marker and assessed the stability of the TTR tetramer ex vivo. The TTR stabilization assay quantifies immunoturbidimetric measurement of the stable TTR tetramer in plasma pre- and post-treatment with 2-day in vitro denaturation with urea. Using this proprietary assay, a dose-dependent trend for greater TTR tetramer stabilization is observed for VYNDAQEL 80-mg compared to VYNDAQEL 20-mg. However, the clinical relevance of a higher TTR tetramer stabilization towards cardiovascular outcomes is not known.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=A%20proprietary%20TTR%20stabilization%20assay,cardiovascular%20outcomes%20is%20not%20known.)

> “The recommended dosage is either VYNDAQEL 80 mg (four 20-mg tafamidis meglumine capsules) orally once daily or VYNDAMAX 61 mg (one 61-mg tafamidis capsule) orally once daily.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=The%20recommended%20dosage%20is%20either%20VYNDAQEL,tafamidis%20capsule%29%20orally%20once%20daily.)

> “VYNDAMAX and VYNDAQEL are not substitutable on a per mg basis [see Clinical Pharmacology (12.3)].”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=orally%20once%20daily.-,VYNDAMAX%20and%20VYNDAQEL%20are%20not%20substitutable%20on%20a%20per%20mg,basis%20%5Bsee%20Clinical%20Pharmacology%20%2812.3%29%5D.)

## Subgroup results

<a id="vyndamax-attr-act-subgroups"></a>

### Vyndamax ATTR-ACT trial: were Vyndaqel results consistent across subgroups?

> “Results from the F-S method represented by win ratio for the combined endpoint and its components (all-cause mortality and frequency of CV-related hospitalization) consistently favored VYNDAQEL versus placebo across all subgroups (wild-type, variant and NYHA Class I & II, and III), except for CV-related hospitalization frequency in NYHA Class III (Figure 4). Win ratio is the number of pairs of VYNDAQEL-treated patient "wins" divided by number of pairs of placebo patient "wins." Analyses of 6MWT and KCCQ-OS also favored VYNDAQEL relative to placebo within each subgroup.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=Results%20from%20the%20F%2DS%20method,to%20placebo%20within%20each%20subgroup.)

Note: ATTR-ACT studied VYNDAQEL (tafamidis meglumine) 20 mg and 80 mg, pooled. The label recommends VYNDAQEL 80 mg or VYNDAMAX 61 mg once daily and states that the two are not substitutable on a per mg basis; the Vyndamax HCP site states that VYNDAMAX approval was based on ATTR-ACT and that one VYNDAMAX 61-mg capsule is bioequivalent to VYNDAQEL 80 mg. In ATTR-ACT, patients received study drug once daily for 30 months.

## Long-term results

<a id="vyndamax-five-year-survival"></a>

### Vyndaqel and Vyndamax: what was 5-year survival in the ATTR-ACT extension?

> “The long-term extension, post hoc, interim analysis compared patients who first received<sup>1</sup>:
>
> VYNDAQEL 80 mg, continuing with VYNDAQEL 80 mg, then transitioned to VYNDAMAX (continuous VYNDAQEL/VYNDAMAX)
> Placebo who were randomized (2:1) to VYNDAQEL 80 mg or 20 mg,<sup>||</sup> then transitioned to VYNDAMAX (placebo to VYNDAQEL/VYNDAMAX)
> The VYNDAQEL 20-mg arm in ATTR-ACT was not included in this analysis”

Source: [VYNDAMAX: Additional Clinical Data | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/additional-data#:~:text=The%20long%2Dterm%20extension%2C%20post%20hoc%2C,not%20included%20in%20this%20analysis)

> “The data reported on the long-term efficacy and safety of tafamidis are from the long-term extension to the ATTR-ACT trial and are not included in the VYNDAQEL/VYNDAMAX prescribing information.”

Source: [VYNDAMAX: Additional Clinical Data | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/additional-data#:~:text=The%20data%20reported%20on%20the,in%20the%20VYNDAQEL%2FVYNDAMAX%20prescribing%20information.)

> “The updated analysis with long-term survival was not prespecified. No formal hypothesis testing was performed given that the overall survival endpoint was met in ATTR-ACT study. This analysis of the long-term extension was not powered to make conclusions on all-cause mortality at 5 years”

Source: [VYNDAMAX: Additional Clinical Data | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/additional-data#:~:text=The%20updated%20analysis%20with%20long%2Dterm,all%2Dcause%20mortality%20at%205%20years)

> “The preliminary 5-year survival rate in this interim analysis was 53% with continuous VYNDAQEL/VYNDAMAX treatment vs 32% in the placebo-to-VYNDAQEL/VYNDAMAX group<sup>1</sup>”

Source: [VYNDAMAX: Additional Clinical Data | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/additional-data#:~:text=The%20preliminary%205%2Dyear%20survival%20rate,vs%2032%25%20in%20the%20placebo%2Dto%2DVYNDAQEL%2FVYNDAMAX)

> “The median follow-up was 58.5 months (continuous tafamidis group) and 57.1 months (placebo-to-tafamidis group)<sup>1</sup>”

Source: [VYNDAMAX: Additional Clinical Data | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/additional-data#:~:text=The%20median%20follow%2Dup%20was%2058.5,group%29%20and%2057.1%20months%20%28placebo%2Dto%2Dtafamidis)

Note: The extension compared continuous tafamidis (VYNDAQEL 80 mg, then VYNDAMAX) with patients who received placebo in ATTR-ACT and then tafamidis. The additional data page of the Vyndamax HCP site cites Elliott et al., Circ Heart Fail 2022.

## Related pages
- [Medical information: Vyndamax (tafamidis): Transthyretin amyloid cardiomyopathy](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy)
- [Indication](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/safety)
- [Specific populations](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/guidelines)
